Neurizon announces leadership transition
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Neurizon Therapeutics Limited announces a leadership transition as Dr. Michael Thurn resigns as Managing Director and CEO, effective immediately, while remaining a Non-Executive Director until July. Mr. Sergio Duchini will serve as Executive Chair during the search for a new CEO to ensure continuity in leadership and ongoing clinical programs. The company has engaged an executive search firm to assist in finding a suitable replacement for Dr. Thurn. The announcement highlights Dr. Thurn's contributions to the company's development and ongoing clinical initiatives.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Appendix 4D - Half-year Financial Report - 31 December 2025
- Appendix 4C & Quarterly Update
- Neurizon secures $6million R&D Tax Incentive Rebate
Later from Neurizon Therapeutics
- NUZ-001 Data Shows Multi-Pathway Protein Clearance
- Placement of Entitlement Offer Shortfall
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics